[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: C (contradiction). Verdict: The keyed answer C is the intended best answer based on the specific RYR2 exon 3 mutation and the presence of exercise‑triggered bidirectional VT, but the item is internally inconsistent. Key stem clues: RYR2 exon 3 p.Arg2474Ser mutation, syncope during competitive swimming, bidirectional VT at 180 bpm, QTc 410 ms, and the contradictory phrase “genotype‑positive, phenotype‑negative.” Main logical issue: The stem states the patient is phenotype‑negative yet describes a clear phenotype (syncope, VT), creating a direct contradiction that undermines the vignette’s reliability. Additionally, prior therapy is not mentioned, which could affect the assessment of “most likely to prevent recurrence.” Main medical accuracy issue: The explanation correctly notes that certain RYR2 mutations may have reduced beta‑blocker response and that flecainide can reduce calcium leak, but the dosing (100 mg twice daily) is not weight‑based for a 14‑year‑old, and the answer omits exercise restriction, which is a cornerstone of CPVT management. Minimal fix: Delete “phenotype‑negative” and add a clause such as “previously untreated” to clarify baseline status, ensuring the stem is internally consistent.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (contradiction). Verdict: The keyed answer C is the intended best answer based on the specific RYR2 exon 3 mutation and the presence of exercise‑triggered bidirectional VT, but the item is internally inconsistent. Key stem clues: RYR2 exon 3 p.Arg2474Ser mutation, syncope during competitive swimming, bidirectional VT at 180 bpm, QTc 410 ms, and the contradictory phrase “genotype‑positive, phenotype‑negative.” Main logical issue: The stem states the patient is phenotype‑negative yet describes a clear phenotype (syncope, VT), creating a direct contradiction that undermines the vignette’s reliability. Additionally, prior therapy is not mentioned, which could affect the assessment of “most likely to prevent recurrence.” Main medical accuracy issue: The explanation correctly notes that certain RYR2 mutations may have reduced beta‑blocker response and that flecainide can reduce calcium leak, but the dosing (100 mg twice daily) is not weight‑based for a 14‑year‑old, and the answer omits exercise restriction, which is a cornerstone of CPVT management. Minimal fix: Delete “phenotype‑negative” and add a clause such as “previously untreated” to clarify baseline status, ensuring the stem is internally consistent.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). Verdict: Keyed answer B is correct best answer. Stem clues: severe hyperammonemia (920 µmol/L) in a 72‑h neonate, low citrulline and arginine, undetectable urine orotic acid, normal anion gap. This pattern points to proximal urea cycle block—most commonly CPS1 deficiency (or NAGS deficiency). Carglumic acid is a synthetic N‑acetylglutamate analog that directly activates CPS1, bypassing the defect in CPS1 or NAGS deficiency. Other options: phenylbutyrate and arginine require functional CPS1 to excrete nitrogen; hemodialysis is temporizing; protein restriction is nonspecific. Thus B is uniquely defensible. Logical issues: None; the stem provides sufficient discriminators to select a single best answer. Medical accuracy: The explanation misstates mechanism (carglumic acid does not increase CPS1’s affinity for NAG; it binds the allosteric site directly) and incorrectly claims CPS1 deficiency is the only responsive disorder (NAGS deficiency also responds). This is a minor inaccuracy but does not undermine the correct answer. Minimal fix: Revise explanation to state that carglumic acid is a synthetic NAG analog that directly activates CPS1 and is effective in both CPS1 and NAGS deficiency.\",\n\"medical_accuracy_score\":   \t\"3\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Keyed answer B is correct best answer. Stem clues: severe hyperammonemia (920 µmol/L) in a 72‑h neonate, low citrulline and arginine, undetectable urine orotic acid, normal anion gap. This pattern points to proximal urea cycle block—most commonly CPS1 deficiency (or NAGS deficiency). Carglumic acid is a synthetic N‑acetylglutamate analog that directly activates CPS1, bypassing the defect in CPS1 or NAGS deficiency. Other options: phenylbutyrate and arginine require functional CPS1 to excrete nitrogen; hemodialysis is temporizing; protein restriction is nonspecific. Thus B is uniquely defensible. Logical issues: None; the stem provides sufficient discriminators to select a single best answer. Medical accuracy: The explanation misstates mechanism (carglumic acid does not increase CPS1’s affinity for NAG; it binds the allosteric site directly) and incorrectly claims CPS1 deficiency is the only responsive disorder (NAGS deficiency also responds). This is a minor inaccuracy but does not undermine the correct answer. Minimal fix: Revise explanation to state that carglumic acid is a synthetic NAG analog that directly activates CPS1 and is effective in both CPS1 and NAGS deficiency.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: thumbnail-sized jellyfish off Great Barrier Reef, delayed severe lower back pain, dyspnea, pulmonary edema, systolic BP 190 mmHg. These point to Irukandji syndrome (Carukia barnesi). The question asks for therapy that specifically antagonizes the pathophysiologic cascade of massive catecholamine release. Magnesium sulfate inhibits catecholamine release and reduces presynaptic calcium influx, directly countering the cascade; it is recommended for severe Irukandji syndrome. Alternatives: Chironex antivenom is ineffective; calcium may worsen catecholamine release; fentanyl provides only analgesia; verapamil is not standard and does not target the sodium‑channel mediated release. No internal contradictions; the stem uniquely identifies the condition and the best therapy. Medical accuracy: The mechanism and recommendation align with current Australian guidelines and literature; dosing is appropriate. No major inaccuracies. Minimal fix: None required.\",\n\"medical_accuracy_score\":  \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: thumbnail-sized jellyfish off Great Barrier Reef, delayed severe lower back pain, dyspnea, pulmonary edema, systolic BP 190 mmHg. These point to Irukandji syndrome (Carukia barnesi). The question asks for therapy that specifically antagonizes the pathophysiologic cascade of massive catecholamine release. Magnesium sulfate inhibits catecholamine release and reduces presynaptic calcium influx, directly countering the cascade; it is recommended for severe Irukandji syndrome. Alternatives: Chironex antivenom is ineffective; calcium may worsen catecholamine release; fentanyl provides only analgesia; verapamil is not standard and does not target the sodium‑channel mediated release. No internal contradictions; the stem uniquely identifies the condition and the best therapy. Medical accuracy: The mechanism and recommendation align with current Australian guidelines and literature; dosing is appropriate. No major inaccuracies. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: recurrent lacunar strokes, livedo racemosa, systemic necrotizing vasculitis without immune complex deposition, low IgM, ADA2 biallelic loss-of-function mutations → DADA2. The disease-driven cascade includes TNF‑α; both adalimumab and etanercept directly block TNF‑α. The explanation claims etanercept can bind mutant ADA2 and paradoxically worsen inflammation, which is not supported by current literature; anti‑TNF therapy is standard, but no consensus that etanercept is contraindicated or inferior. Therefore, both anti‑TNF options are defensible, making the item ambiguous. The keyed answer (adalimumab) is a reasonable choice, but not uniquely best. Main logical issue: reliance on a non‑evidence‑based mechanistic distinction to eliminate etanercept. Main medical accuracy issue: inclusion of an inaccurate mechanistic claim that could mislead learners. Minimal fix: either remove the claim and accept both anti‑TNF agents as correct, or add a specific clue that the patient has previously failed etanercept or has a contraindication.\",\"medical_accuracy_score\":  \t\"2\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: recurrent lacunar strokes, livedo racemosa, systemic necrotizing vasculitis without immune complex deposition, low IgM, ADA2 biallelic loss-of-function mutations → DADA2. The disease-driven cascade includes TNF‑α; both adalimumab and etanercept directly block TNF‑α. The explanation claims etanercept can bind mutant ADA2 and paradoxically worsen inflammation, which is not supported by current literature; anti‑TNF therapy is standard, but no consensus that etanercept is contraindicated or inferior. Therefore, both anti‑TNF options are defensible, making the item ambiguous. The keyed answer (adalimumab) is a reasonable choice, but not uniquely best. Main logical issue: reliance on a non‑evidence‑based mechanistic distinction to eliminate etanercept. Main medical accuracy issue: inclusion of an inaccurate mechanistic claim that could mislead learners. Minimal fix: either remove the claim and accept both anti‑TNF agents as correct, or add a specific clue that the patient has previously failed etanercept or has a contraindication.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. This GCK-MODY vignette contains all necessary discriminators: young non-obese patient with mild, stable fasting hyperglycemia (108-115 mg/dL), HbA1c 6.1-6.3%, negative autoantibodies, and dominant family history. The identified heterozygous GCK pathogenic variant confirms the diagnosis. The question's focus on 'longitudinal natural history data' precisely targets the evidence-based management principle for GCK-MODY. Key stem clues drive unambiguously to option D: (1) mild stable glycemia, (2) genetic confirmation, (3) normal BMI, and (4) parental history consistent with autosomal dominant inheritance. The keyed answer D ('No pharmacologic therapy') aligns with robust cohort data showing no increased microvascular/macrovascular complications and no glycemic benefit from treatment. Alternative options are clearly inferior: metformin (A) and sitagliptin (C) lack evidence of efficacy; glipizide (B) is explicitly ineffective as sulfonylureas cannot correct the glucokinase sensing defect; basal insulin (E) is inappropriate for this non-progressive, non-insulin-dependent condition. No logical flaws, contradictions, or missing critical details. Medical content is accurate, current, and board-relevant. Minimal fix: none required.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. This GCK-MODY vignette contains all necessary discriminators: young non-obese patient with mild, stable fasting hyperglycemia (108-115 mg/dL), HbA1c 6.1-6.3%, negative autoantibodies, and dominant family history. The identified heterozygous GCK pathogenic variant confirms the diagnosis. The question's focus on 'longitudinal natural history data' precisely targets the evidence-based management principle for GCK-MODY. Key stem clues drive unambiguously to option D: (1) mild stable glycemia, (2) genetic confirmation, (3) normal BMI, and (4) parental history consistent with autosomal dominant inheritance. The keyed answer D ('No pharmacologic therapy') aligns with robust cohort data showing no increased microvascular/macrovascular complications and no glycemic benefit from treatment. Alternative options are clearly inferior: metformin (A) and sitagliptin (C) lack evidence of efficacy; glipizide (B) is explicitly ineffective as sulfonylureas cannot correct the glucokinase sensing defect; basal insulin (E) is inappropriate for this non-progressive, non-insulin-dependent condition. No logical flaws, contradictions, or missing critical details. Medical content is accurate, current, and board-relevant. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (valid). Verdict: The keyed answer B is the correct best choice. The stem provides classic AL amyloidosis cardiac biomarkers (LV wall thickness 15 mm, global longitudinal strain –8 %, apical sparing ratio 2.5) and a markedly elevated free light‑chain difference, establishing a diagnosis of cardiac AL amyloidosis. The question asks which regimen has shown a survival benefit in stage IIIb disease. Among the options, only daratumumab‑bortezomib‑dexamethasone (Dara‑VCd) has prospective randomized evidence (ANDROMEDA trial) of improved overall survival in high‑risk AL amyloidosis. The other choices are either standard of care without proven survival gain (VCd), organ‑directed therapy not appropriate for AL (tafamidis), investigational (doxycycline), or not a drug regimen (heart transplant). Thus a single best answer is defensible. Minor medical accuracy issue: ANDROMEDA excluded patients with NT‑proBNP > 8500 ng/L (stage IIIb), so the evidence for a survival benefit specifically in stage IIIb is indirect; the regimen is recommended for high‑risk disease overall. Minimal fix: Replace \\\"stage IIIb\\\" with \\\"high‑risk (stage IIIa/IIIb) cardiac AL amyloidosis\\\" to align the wording with the trial population.\",\n\"medical_accuracy_score\":  \t\"3\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (valid). Verdict: The keyed answer B is the correct best choice. The stem provides classic AL amyloidosis cardiac biomarkers (LV wall thickness 15 mm, global longitudinal strain –8 %, apical sparing ratio 2.5) and a markedly elevated free light‑chain difference, establishing a diagnosis of cardiac AL amyloidosis. The question asks which regimen has shown a survival benefit in stage IIIb disease. Among the options, only daratumumab‑bortezomib‑dexamethasone (Dara‑VCd) has prospective randomized evidence (ANDROMEDA trial) of improved overall survival in high‑risk AL amyloidosis. The other choices are either standard of care without proven survival gain (VCd), organ‑directed therapy not appropriate for AL (tafamidis), investigational (doxycycline), or not a drug regimen (heart transplant). Thus a single best answer is defensible. Minor medical accuracy issue: ANDROMEDA excluded patients with NT‑proBNP > 8500 ng/L (stage IIIb), so the evidence for a survival benefit specifically in stage IIIb is indirect; the regimen is recommended for high‑risk disease overall. Minimal fix: Replace \"stage IIIb\" with \"high‑risk (stage IIIa/IIIb) cardiac AL amyloidosis\" to align the wording with the trial population.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: M (multiple answers defensible) – secondary U (underspecified). Verdict: The keyed answer (C) is not uniquely determinable; B is equally plausible. Stem clues: 4‑day‑old neonate, burst‑suppression EEG, multifocal seizures refractory to phenobarbital and levetiracetam, de novo KCNQ2 gain‑of‑function mutation. These point to a channelopathy responsive to sodium‑channel blockade. However, both B (phenytoin) and C (carbamazepine) share the same mechanism; the vignette offers no discriminating feature (e.g., age‑specific safety, pharmacokinetics, spectrum of sodium‑channel subtypes) to prefer carbamazepine over phenytoin. Consequently, two options are defensible as “most likely,” violating the single‑best‑answer requirement. Medical accuracy: The explanation correctly identifies sodium‑channel blockade as effective in KCNQ2 gain‑of‑function seizures and notes that phenobarbital/levetiracetam are often ineffective. No major factual errors, but the omission of any rationale for choosing carbamazepine over phenytoin is a minor omission. Minimal fix: Replace phenytoin (B) with a non–sodium‑channel mechanism (e.g., GABA‑A modulator or SV2A ligand) or add a stem detail that specifically supports carbamazepine (e.g., “carbamazepine is preferred in neonates with this genotype”).\",\n\"medical_accuracy_score\":  \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t \t  \"4\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (multiple answers defensible) – secondary U (underspecified). Verdict: The keyed answer (C) is not uniquely determinable; B is equally plausible. Stem clues: 4‑day‑old neonate, burst‑suppression EEG, multifocal seizures refractory to phenobarbital and levetiracetam, de novo KCNQ2 gain‑of‑function mutation. These point to a channelopathy responsive to sodium‑channel blockade. However, both B (phenytoin) and C (carbamazepine) share the same mechanism; the vignette offers no discriminating feature (e.g., age‑specific safety, pharmacokinetics, spectrum of sodium‑channel subtypes) to prefer carbamazepine over phenytoin. Consequently, two options are defensible as “most likely,” violating the single‑best‑answer requirement. Medical accuracy: The explanation correctly identifies sodium‑channel blockade as effective in KCNQ2 gain‑of‑function seizures and notes that phenobarbital/levetiracetam are often ineffective. No major factual errors, but the omission of any rationale for choosing carbamazepine over phenytoin is a minor omission. Minimal fix: Replace phenytoin (B) with a non–sodium‑channel mechanism (e.g., GABA‑A modulator or SV2A ligand) or add a stem detail that specifically supports carbamazepine (e.g., “carbamazepine is preferred in neonates with this genotype”).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides classic CADASIL clues: young woman with migraine with aura, acute hemiparesis, MRI T2 hyperintensities in anterior temporal lobe and external capsule. These findings point to small‑vessel disease with fragile arterioles. The disease‑specific pathophysiology makes IV tPA relatively contraindicated because of heightened hemorrhagic risk; this matches the keyed answer A. Alternative options are not contraindicated: aspirin and clopidogrel are standard antiplatelet therapies, supportive care is always appropriate, and mechanical thrombectomy is not indicated for lacunar strokes but is not a contraindication. The item therefore yields a single best answer. Logical issues: none. Medical accuracy: The answer aligns with expert caution regarding thrombolysis in CADASIL; however, current AHA/ASA guidelines do not list CADASIL as a formal contraindication, and the explanation’s claim that mechanical thrombectomy is also contraindicated is inaccurate. These are minor issues. Minimal fix: Revise the explanation to delete the statement about mechanical thrombectomy being contraindicated and note that tPA is relatively contraindicated per expert opinion.\",\n\"medical_accuracy_score\":  \t \t \t \t\"3\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides classic CADASIL clues: young woman with migraine with aura, acute hemiparesis, MRI T2 hyperintensities in anterior temporal lobe and external capsule. These findings point to small‑vessel disease with fragile arterioles. The disease‑specific pathophysiology makes IV tPA relatively contraindicated because of heightened hemorrhagic risk; this matches the keyed answer A. Alternative options are not contraindicated: aspirin and clopidogrel are standard antiplatelet therapies, supportive care is always appropriate, and mechanical thrombectomy is not indicated for lacunar strokes but is not a contraindication. The item therefore yields a single best answer. Logical issues: none. Medical accuracy: The answer aligns with expert caution regarding thrombolysis in CADASIL; however, current AHA/ASA guidelines do not list CADASIL as a formal contraindication, and the explanation’s claim that mechanical thrombectomy is also contraindicated is inaccurate. These are minor issues. Minimal fix: Revise the explanation to delete the statement about mechanical thrombectomy being contraindicated and note that tPA is relatively contraindicated per expert opinion.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (U). Verdict: Correct best answer (anakinra) but item allows multiple defensible choices. Key stem clues: lifelong recurrent high fevers >38.5°C, severe abdominal pain, myalgia, periorbital edema, and a pathogenic TNFRSF1A cysteine mutation—classic for TRAPS. The question asks which biologic therapy is preferred over etanercept due to mechanistic considerations. Both anakinra (IL‑1R antagonist) and canakinumab (anti‑IL‑1β) bypass the mutant TNF‑R1 pathway and are effective; current practice often uses anakinra first‑line, but the stem does not specify “first‑line” or “initial,” making canakinumab equally plausible. Thus two options are defensible, yielding multiple answers. No medical inaccuracies: anakinra is indeed a first‑line IL‑1 blocker for TRAPS, and the rationale that etanercept can bind mutant TNF‑R1 and prolong inflammation is correct. Colchicine is ineffective for TRAPS, and tocilizumab is not used. Minimal fix: insert “first‑line” in the stem (e.g., “Which biologic therapy is preferred as first‑line therapy over etanercept…”) to eliminate ambiguity and render a single best answer.\",\n\"medical_accuracy_score\":  \t \t \t \t\"5\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (U). Verdict: Correct best answer (anakinra) but item allows multiple defensible choices. Key stem clues: lifelong recurrent high fevers >38.5°C, severe abdominal pain, myalgia, periorbital edema, and a pathogenic TNFRSF1A cysteine mutation—classic for TRAPS. The question asks which biologic therapy is preferred over etanercept due to mechanistic considerations. Both anakinra (IL‑1R antagonist) and canakinumab (anti‑IL‑1β) bypass the mutant TNF‑R1 pathway and are effective; current practice often uses anakinra first‑line, but the stem does not specify “first‑line” or “initial,” making canakinumab equally plausible. Thus two options are defensible, yielding multiple answers. No medical inaccuracies: anakinra is indeed a first‑line IL‑1 blocker for TRAPS, and the rationale that etanercept can bind mutant TNF‑R1 and prolong inflammation is correct. Colchicine is ineffective for TRAPS, and tocilizumab is not used. Minimal fix: insert “first‑line” in the stem (e.g., “Which biologic therapy is preferred as first‑line therapy over etanercept…”) to eliminate ambiguity and render a single best answer.", "medical_accuracy_score": 5, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. Key clues: 21-year-old woman, hypertension, 4-cm adrenal mass, plasma normetanephrine 8.2 nmol/L (13.7× ULN), pathogenic SDHB variant. The stem posits SDHB tumors have unique catecholamine synthesis requiring phenoxybenzamine plus metyrosine. However, standard preoperative preparation for pheochromocytoma is alpha-blockade alone (option A), with metyrosine as an optional adjunct per Endocrine Society guidelines—not a mandatory requirement for any genotype. No clinical features (e.g., catecholamine levels >10× ULN, prior hypertensive crisis, refractory hypertension) differentiate why combination therapy is specifically required here, making option A equally defensible. Medical accuracy: The claim that SDHB tumors mandatorily require metyrosine overstates evidence; this genotype is associated with higher synthesis but not a guideline-mandated indication for dual blockade. Score: 3 (minor issues—nonstandard emphasis). Logical validity: false. Reason: M. Minimal fix: Add detail such as 'persistent severe hypertension despite alpha-blockade' or 'catecholamine levels >15× ULN' to justify mandatory synthesis inhibition.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. Key clues: 21-year-old woman, hypertension, 4-cm adrenal mass, plasma normetanephrine 8.2 nmol/L (13.7× ULN), pathogenic SDHB variant. The stem posits SDHB tumors have unique catecholamine synthesis requiring phenoxybenzamine plus metyrosine. However, standard preoperative preparation for pheochromocytoma is alpha-blockade alone (option A), with metyrosine as an optional adjunct per Endocrine Society guidelines—not a mandatory requirement for any genotype. No clinical features (e.g., catecholamine levels >10× ULN, prior hypertensive crisis, refractory hypertension) differentiate why combination therapy is specifically required here, making option A equally defensible. Medical accuracy: The claim that SDHB tumors mandatorily require metyrosine overstates evidence; this genotype is associated with higher synthesis but not a guideline-mandated indication for dual blockade. Score: 3 (minor issues—nonstandard emphasis). Logical validity: false. Reason: M. Minimal fix: Add detail such as 'persistent severe hypertension despite alpha-blockade' or 'catecholamine levels >15× ULN' to justify mandatory synthesis inhibition.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]